Intranasal Esketamine (Spravato™) for Use in Treatment-Resistant Depression In Conjunction With an Oral Antidepressant
P&T (Pharmacy & Therapeutics)
Publication Date / Copyright Date
340; 344; 375
342; 346; 375
Major depressive disorder (MDD) affects more than 16 million adults each year in the United States.1 The incomplete response that many persons experience with current antidepressant (AD) therapies is one factor contributing to the difficulty of successfully treating MDD.2 Approximately 30% of patients meet the criteria for treatment-resistant depression (TRD), having no positive therapeutic response even after trying two or more AD medications. 2 According to the World Health Organization (WHO), depression is the leading cause of disability worldwide.3 Untreated depression is a major risk factor for suicide: Each year, approximately 800,000 people–– one person every 40 seconds––successfully complete suicide.4,5 Many patients with MDD are at risk for poor outcomes because of the limitations of currently approved treatments.6 These incomplete or poor responses to traditional ADs have led to the off-label use of many novel substances for the treatment of MDD.
Medicine and Health Sciences | Pharmacy and Pharmaceutical Sciences
antidepressant, intranasal esketamine (Spravato™); major depressive disorder (MDD), treatment
Bahr, Rebecca; Lopez, Alicia; and Rey, Jose A., "Intranasal Esketamine (Spravato™) for Use in Treatment-Resistant Depression In Conjunction With an Oral Antidepressant" (2019). Faculty Articles. 337.